Ovarian Cancer

Rucaparib is an oral, small molecule inhibitor being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers.

FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.

A first-in-class targeted therapy, VB-111 is administered by intravenous infusion once every 6 to 8 weeks.

Several recent studies presented at the virtual SGO 2020 Annual Meeting on Women’s Cancer looked into veliparib, a potential anticancer PARP inhibitor, for treatment of various types of ovarian cancer.

The JAVELIN trial is a randomized, open-label, phase 3 trial comparing avelumab in combination with chemotherapy versus chemotherapy alone.

Researchers presented findings in conjunction with the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer on the phase 3 VELIA trial studying the safety of veliparib.

PARP inhibitors are novel therapies with indication focused on ovarian cancer; however, new agents are being studied for other cancers as well.

Clinical trials are now evaluating the potential combination of PARP inhibitors with immunotherapy or other agents in patients with ovarian cancer.

Ovarian cancer has been dubbed "the silent killer" because of its overall 5-year survival rate of 47%: By the time a woman receives the diagnosis, the prognosis is unfavorable.